Welcome to our dedicated page for Omnicell Com news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell Com stock.
Omnicell, Inc. (OMCL) delivers innovative healthcare automation solutions that optimize medication management and supply chain operations across care settings. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's operational developments, financial performance, and technological advancements.
Access comprehensive coverage of Omnicell's latest announcements including earnings reports, product innovations, strategic partnerships, and industry recognition. Our curated news collection enables stakeholders to track the company's progress in enhancing clinical workflows through automated dispensing systems and data-driven analytics solutions.
Stay informed about OMCL initiatives that impact healthcare efficiency, from pharmacy automation platforms to inventory management technologies. The resource serves as a centralized repository for monitoring how Omnicell continues to address critical challenges in medication safety and operational cost control.
Bookmark this page for ongoing updates on Omnicell's contributions to healthcare technology, including system implementations, regulatory milestones, and market expansion efforts. Check regularly for verified information supporting informed analysis of the company's position in the healthcare IT sector.
Omnicell (NASDAQ:OMCL) announced strong Q2 2024 results, exceeding guidance across all metrics. Total revenues were $277 million, down 7% year-over-year. GAAP net income was $0.08 per diluted share, while non-GAAP net income reached $0.51 per diluted share. The company reported $557 million in cash and cash equivalents and $571 million in total debt. Omnicell raised its 2024 non-GAAP EBITDA and earnings per share guidance, projecting full-year revenues between $1.070 billion and $1.110 billion. The company's XT Amplify program is gaining market momentum, and strategic partnerships are enhancing pharmacy performance. Omnicell remains focused on innovation and streamlining operations to drive long-term growth and shareholder returns.
Omnicell, Inc. (Nasdaq:OMCL), a leader in pharmacy care delivery transformation, has announced the release of its second quarter 2024 financial results on August 1, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Interested parties can join the call by dialing (800) 715-9871 in the U.S. or (646) 307-1963 internationally, using the Conference ID 3278878. A live and archived webcast will be available on Omnicell's Investor Relations website.
Omnicell, Inc. (OMCL) will be presenting at the BofA Securities 2024 Health Care Conference in Las Vegas, NV. The presentation will take place on May 15, 2024, at 3:40 p.m. PT. The event will be live-streamed and available for viewing on the Omnicell website.
Omnicell, Inc. (NASDAQ:OMCL) announced first quarter 2024 results, exceeding guidance with total GAAP revenues of $246 million. The company reported a challenging environment for some health system customers affecting revenues. Omnicell highlighted new solutions for their XT automated dispensing systems and ongoing efforts to enhance shareholder value. Financially, the company reported a net loss of $16 million, non-GAAP net income of $1 million, and non-GAAP EBITDA of $11 million. With a strong balance sheet, Omnicell aims to transform the pharmacy care delivery model and continues to innovate in the industry.
FAQ
What is the current stock price of Omnicell Com (OMCL)?
What is the market cap of Omnicell Com (OMCL)?
